Paraoxonase-1 promoter polymorphism C - 107T and serum apolipoprotein AI interact to modulate serum paraoxonase-1 status

Pharmacogenetics and Genomics

Volumn 15, Issue 6, 2005, Pages 441-446

  James, Richard W ^a   Kalix, Barbara ^a   Bioletto, Silvana ^a   Brulhart Meynet, Marie Claude ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Atherosclerosis; Lipoprotein; Organophosphate; Oxidative stress; Polymorphism

Indexed keywords

APOLIPOPROTEIN A1; ARGININE; ARYLDIALKYLPHOSPHATASE; CYTOSINE; GLUTAMINE; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; ORGANOPHOSPHATE; THYMINE;

ADULT; AGED; AGING; AMINO ACID SUBSTITUTION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME SPECIFICITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MOLECULAR WEIGHT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SMOKING;

EID: 20644436041     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200506000-00011     Document Type: Article

References (45)

1. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. Thematic review series: The pathogenesis of atherosclerosis: The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45:993-1007.
2. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004; 107:435-447.
3. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69:541-550.
4. Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF. Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 2000; 31:1487-1493.
5. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W (ed.). Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992. pp. 51-91.
6. Leviev I, James RW. Promoter polymorphisms of the human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20:516-521.
7. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15:1812-1818.
8. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
9. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138:271-280.
10. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998; 9:2082-2088.
11. Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999; 147:405-410.
12. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in coronary artery disease patients. Circulation 2000; 101:2252-2257.
13. Araki S, Makita Y, Canani L, Ng D, Warram J H, Krolewski AS. Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in type I diabetes mellitus. Diabetologia 2000; 43:1540-1543.
14. Senti M, Aubo C, Elosua R, Sala J, Tomas M, Marrugat J. Effect of physical activity on lipid levels in a population-based sample of men with and without the Arg192 variant of the human paraoxonase gene. Genet Epidemiol 2000; 18:276-286.
15. Boemi M, Leviev I, Sirolla C, Pieri C, Marra M, James RW. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 2001; 155:229-235.
16. Oda MN, Bielicki JK, Berger T, Forte TM. Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry 2001; 40:1710-1718.
17. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22:1329-1333.
18. Blatter-Garin MC, Kalix B, DePree S, James RW. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia 2003; 46:593-594.
19. Blatter-Garin M-C, Abbot C, Messmer S, Mackness MI, Durrington P, Pometta D, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994; 304:549-554.
20. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21:1451-1457.
21. Boemi M, Sirolla C, Testa R, Cenerelli S, Fumelli P, James RW. Smoking is associated with reduced serum levels of the antioxidant enzyme, paraoxonase, in Type 2 diabetic patients. Diabet Med 2004; 21:423-427.
22. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Rad Biol Med 1999; 26:892-904.
23. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 1998; 78:547-581.
24. Vlassara H, Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning? Rev Endocr Metab Disord. 2004; 5:181-188.
25. Morrow JD, Frei B, Longmire AW, Gaziono JM, Lynch SM, Shyr Y, et al. Increases in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 1995; 332:1198-1203.
26. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89:4963-4971.
27. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 2001; 79:457-463.
28. James RW, Pometta D. Differences in lipoprotein subfraction composition and distribution between type 1 diabetic men and control subjects. Diabetes 1990; 39:1158-1164.
29. Blatter-Garin M-C, James RW, Dussoix P, Blanché H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99:62-66.
30. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001; 68:1428-1436.
31. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745-753.
32. Brophy VH, Jarvik GP, Richter RJ, Rozek LS, Schellenberg GD, Furlong CE. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 2000; 10:453-460.
33. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-2447.
34. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 2000; 150:295-298.
35. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001; 11:77-84.
36. Jarvik GP, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA, et al. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 2003; 13:291-295.
37. Josse D, Ebel C, Stroebel D, Fontaine A, Borges F, Echalier A, et al. Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1). J Biol Chem 2002; 277:33386-33397.
38. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 2004; 11:412-419.
39. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473-480.
40. Marsh JB, Welty FK, Schaefer EJ. Stable isotope turnover of apolipoproteins of high density lipoproteins in humans. Curr Opin Lipidol 2000; 11:261-266.
41. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002; 277:4301-4308.
42. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399-1402.
43. Ansell BJ, Navab M, Watson KE, Fonarow GC, Fogelman AM. Anti-inflammatory properties of HDL. Rev Endocr Metab Disord 2004; 5:351-358.
44. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 2001; 276:34480-34485.
45. vonEckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21:13-27.